Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ANNOUNCED NOVARTIS AGREEMENT TO ACQUIRE AVIDITY FOR TOTAL EQUITY VALUE OF APPROXIMATELY $12 BILLION; AVIDITY EXPECTS TO SEPARATE ITS EARLY-STAGE PRECISION CARDIOLOGY PROGRAMS INTO A NEW PUBLIC COMPANY ("SPINCO") CLEAR PATH FORWARD ALIGNED WITH FDA FOLLOWING PRE-BLA MEETING FOR DEL-ZOTA, WITH BLA SUBMISSION PLANNED FOR 2026 DEL-ZOTA ONE-YEAR DATA DEMONSTRATED SUSTAINED MUSCLE PROTECTION LEADING TO MEANINGFUL IMPROVEMENT AND REVERSAL OF DISEASE PROGRESSION ACROSS MULTIPLE KEY FUNCTIONAL MEASURES STRONG BALANCE SHEET WITH ~$1.9 BILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES SAN DIEGO , NOV. 10, 2025 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. (NASDAQ: RNA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOCS) TO PROFOUNDLY IMPROVE PEOPLE'S LIVES, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND HIGHLIGHTED RECENT PROGRESS. "IN OCTOBER, WE ANNOUNCED THAT AVIDITY ENTERED INTO A DEFINITIVE MERGER AGREEMENT WITH NOVARTIS, WHICH WE BELIEVE MAXIMIZES VALUE FOR OUR INVESTORS, ACCELERATES THE GLOBAL REACH OF OUR INNOVATIVE NEUROSCIENCE PIPELINE, AND ADVANCES EVEN MORE POSSIBILITIES FOR OUR INNOVATIVE SCIENCE," SAID SARAH BOYCE, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF AVIDITY.

AVIDITY BIOSCIENCES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF AVIDITY BIOSCIENCES, INC. (NASDAQGM: RNA) TO NOVARTIS AG. UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF AVIDITY WILL RECEIVE $72.00 IN CASH FOR EACH SHARE OF AVIDITY THAT THEY OWN. KSF IS SEEKING TO DETERMINE WHETHER THIS CONSIDERATION AND THE PROCESS THAT LED TO IT ARE ADEQUATE, OR W.

AVIDITY BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF AVIDITY BIOSCIENCES, INC. - RNA

NOVARTIS TO ACQUIRE AVIDITY FOR USD 72.00 PER SHARE IN CASH FOR TOTAL EQUITY VALUE OF APPROXIMATELY USD 12.0 BILLION AVIDITY EXPECTS TO SEPARATE ITS EARLY-STAGE PRECISION CARDIOLOGY PROGRAMS INTO A NEW COMPANY ("SPINCO") CLOSING EXPECTED IN 1H2026 SUBJECT TO COMPLETION OF THE SEPARATION OF SPINCO FROM AVIDITY AND OTHER CUSTOMARY CLOSING CONDITIONS SAN DIEGO , OCT. 26, 2025 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. ("AVIDITY") (NASDAQ: RNA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES ("AOCS") TO PROFOUNDLY IMPROVE PEOPLE'S LIVES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A DEFINITIVE MERGER AGREEMENT WITH NOVARTIS AG ("NOVARTIS") WHICH HAS BEEN UNANIMOUSLY APPROVED BY THE BOARDS OF DIRECTORS OF BOTH COMPANIES.THE ACQUISITION WILL FOLLOW THE SEPARATION OF AVIDITY'S EARLY-STAGE PRECISION CARDIOLOGY PROGRAMS INTO SPINCO, WHICH IS EXPECTED TO BE A PUBLICLY TRADED COMPANY.

AVIDITY BIOSCIENCES ENTERS INTO AGREEMENT TO BE ACQUIRED BY NOVARTIS AG

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR TRANSACTION STRENGTHENS NEUROSCIENCE FRANCHISE FOR NOVARTIS WITH THREE LATE-STAGE PROGRAMS THAT ADDRESS GENETIC NEUROMUSCULAR DISEASES ADVANCES THE NOVARTIS XRNA STRATEGY BY ADDING A SCIENTIFICALLY ROBUST, MUSCLE-DIRECTED, ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOCS) PLATFORM AND FIRST-IN-DISEASE PIPELINE EXPECTED TO UNLOCK MULTI-BILLION-DOLLAR OPPORTUNITIES WITH PLANNED PRODUCT LAUNCHES BEFORE 2030 RAISES EXPECTED 2024-2029 SALES CAGR FOR NOVARTIS FROM +5% TO +6%, AND BOLSTERS MID-SINGLE DIGIT LONG-TERM GROWTH AS PART OF THE AGREEMENT, AVIDITY WILL SEPARATE ITS EARLY-STAGE PRECISION CARDIOLOGY PROGRAMS INTO A NEW COMPANY (SPINCO) PRIOR TO CLOSING CONSIDERATION TOTALS USD 12BN IN CASH; CLOSING EXPECTED IN H1 2026 SUBJECT TO COMPLETION OF THE SEPARATION OF SPINCO FROM AVIDITY AND OTHER CUSTOMARY CLOSING CONDITIONS BASEL, OCTOBER 26, 2025  NOVARTIS TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT TO ACQUIRE AVIDITY BIOSCIENCES, INC. (NASDAQ: RNA), A SAN DIEGO-BASED, BIOPHARMACEUTICAL COMPANY FOCUSED ON A NEW CLASS OF THERAPEUTICS ENABLING RNA DELIVERY TO MUSCLE.

NOVARTIS AGREES TO ACQUIRE AVIDITY BIOSCIENCES, AN INNOVATOR IN RNA THERAPEUTICS, STRENGTHENING ITS LATE-STAGE NEUROSCIENCE PIPELINE

SAN DIEGO , OCT. 16, 2025 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. (NASDAQ: RNA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOCS), TODAY ANNOUNCED THAT AVIDITY MANAGEMENT WILL PARTICIPATE IN A PANEL DISCUSSION AT THE FOLLOWING INVESTOR CONFERENCE: CHARDAN 9TH ANNUAL GENETIC MEDICINES CONFERENCE, NEW YORK, NY TUESDAY, OCTOBER 21, 2025, AT11:00A.M. PT/2:00 P.M.

AVIDITY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCE

SAN DIEGO , OCT. 13, 2025 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. (NASDAQ: RNA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOCS) TO PROFOUNDLY IMPROVE PEOPLE'S LIVES, TODAY ANNOUNCED THAT THE COMPANY COMPLETED A POSITIVE PRE-BLA MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) REGARDING ITS UPCOMING BLA SUBMISSION OF DELPACIBART ZOTADIRSEN (DEL-ZOTA). DEL-ZOTA, WHICH RECEIVED BREAKTHROUGH THERAPY DESIGNATION, IS AN INVESTIGATIONAL DRUG BEING EVALUATED AS A POTENTIAL TREATMENT FOR PEOPLE LIVING WITH DUCHENNE MUSCULAR DYSTROPHY WHO HAVE GENE MUTATIONS AMENABLE TO EXON 44 SKIPPING (DMD44).

AVIDITY BIOSCIENCES ANNOUNCES POSITIVE PRE-BLA MEETING WITH U.S. FDA FOR DEL-ZOTA IN DMD44 WITH A SUBMISSION PLANNED FOR Q1 2026

SAN DIEGO , OCT. 6, 2025 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. (NASDAQ: RNA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOCS) TO PROFOUNDLY IMPROVE PEOPLE'S LIVES, TODAY ANNOUNCED THAT IT WILL DELIVER LATE-BREAKING ORAL AND POSTER PRESENTATIONS AT THE 30TH ANNUAL INTERNATIONAL CONGRESS OF THE WORLD MUSCLE SOCIETY (WMS), TO BE HELD OCTOBER 7-11, 2025, IN VIENNA, AUSTRIA. THE DATA TO BE PRESENTED AT WMS WILL REINFORCE AND BUILD ON THE POSITIVE DATA ANNOUNCED BY AVIDITY IN SEPTEMBER 2025 WHICH SHOWED REVERSAL OF DISEASE PROGRESSION AND UNPRECEDENTED IMPROVEMENT COMPARED TO BASELINE AND NATURAL HISTORY ACROSS MULTIPLE FUNCTIONAL MEASURES FOR PARTICIPANTS LIVING WITH DUCHENNE MUSCULAR DYSTROPHY MUTATIONS AMENABLE TO EXON 44 SKIPPING (DMD44) TREATED CONTINUOUSLY WITH DELPACIBART ZOTADIRSEN (DEL-ZOTA) FOR ONE YEAR IN THE PHASE 1/2 EXPLORE44 AND PHASE 2 EXPLORE44-OLE TRIALS.

AVIDITY BIOSCIENCES TO PRESENT DATA FROM EXPLORE44 CLINICAL DEVELOPMENT PROGRAM OF DEL-ZOTA IN DMD44 AT 30TH ANNUAL CONGRESS OF THE WORLD MUSCLE SOCIETY

SAN DIEGO , SEPT. 15, 2025 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. (NASDAQ: RNA),A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOCS), TODAY ANNOUNCED THAT IT HAS CLOSED ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 17,250,000 SHARES OF ITS COMMON STOCK, INCLUDING 2,250,000 SHARES SOLD PURSUANT TO THE UNDERWRITERS' FULL EXERCISE OF THEIR OPTION TO PURCHASE ADDITIONAL SHARES, AT A PRICE TO THE PUBLIC OF $40.00 PER SHARE.

AVIDITY BIOSCIENCES, INC. ANNOUNCES CLOSING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK, INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

SAN DIEGO , SEPT. 11, 2025 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. (NASDAQ: RNA),A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOCS), TODAY ANNOUNCED THE PRICING OF ITSUPSIZEDUNDERWRITTEN PUBLIC OFFERING OF 15,000,000 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $40.00 PER SHARE.

AVIDITY BIOSCIENCES ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK

SAN DIEGO , SEPT. 10, 2025 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. (NASDAQ: RNA),A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOCS), TODAY ANNOUNCED THAT IT INTENDS TO OFFER AND SELL, SUBJECT TO MARKET AND OTHER CONDITIONS, $500.0 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.

Avidity Biosciences, Inc.

RNA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Avidity Biosciences, Inc.

RNA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RNA